Britannica Dictionary Definition Of KEEN
Ability to think clearly and to understand what is not obvious or simple
Our Vision And Mission
Keen Access Insights are proud to be part of an industry that is helping with science and technology to improve people’s lives. Our goal is to help our clients with what they need to bring their innovations to patients that need them: identify unique insights, generate new ideas and drive meaningful results. We help BioPharma, BioTech, MedTech & other healthcare system actors with market access consulting services.
We genuinely love the work that we do and won’t take on a project unless we are passionate about it, in which case we give it our all.
Market Access Consulting & Support
Market Access is the key to successfully commercializing your healthcare innovations. We provide tailored strategic planning tools and methods to shape your early market access strategy, help you to demonstrate the added value of products to ultimately achieve reimbursement and patient access. Our Market Access Consulting services are tailored for Biopharma, Biotech, MedTech, Academic institutions and Healthcare system actors.
Market Landscape & Gap Analysis
Businesses active in the healthcare and life sciences, whether new or established, continuously face a lot of challenges and problems when planning to launch a new product or treatment. Market landscape & gap analysis is one of the most ingenious strategic tools for early problem-solving as it helps you to identify how your product would be positioned in the healthcare system as opposed to where you desire it to be. It gives direction to your commercial choices and the actions you need to take as well as how much resources to put in it to make your market access strategy a success.
Healthcare Policy Analysis & Shaping
Health technology assessment is a policy instrument that guides decision-making by payers and governments. However, despite a pipeline of much wanted or sought for innovations, Biopharma and Biotech companies experience that it is no longer about the added value or the clinical relevance, but the question if payers are able or even willing to pay the price. MedTech covers a wide spectrum of healthcare solutions. But with health technology assessment methodologies still in their infancy, it is difficult to prove the added value which leads to health systems not fully benefitting from technological innovations.
Stakeholder Analysis & Engagement Plans
Many healthcare system actors are influenced by the introduction of new innovations. Although the benefits to stakeholders may sometimes seem obvious, it does not always have the same priority for them as for you. Stakeholder analysis is not a means to influence stakeholders to get from A to B, but a tool to help you ensure that the appropriate stakeholders have been identified based on their interest and influence before deciding to get them engaged. And as stakeholder engagement plans are often executed by cross-functional teams it is important to define clear KPI’s to help to assess the effectiveness of your engagements.
Shaping Commercial Strategy Or Launch Strategy
In the healthcare industry, market access can often only be achieved by satisfying complex health policy decision-making structures using technical information from HEOR studies & cost-effectiveness analysis to guide pricing and budget impact evaluations. Market access is often referred to as a process. However, in the context of (international) trade market access refers to the ability of a company or country to sell goods and services across borders. If market access is seen as the pivotal condition for successful commercialization, it becomes very important to have realistic assumptions of pricing and a keen strategy at an early stage of starting your commercial or launch offer.
Market Access Organizational Development
The time that the market access strategy involved a pricing and reimbursement dossier that was developed in isolation has passed. The market access function has become more diverse and is embedded in national, regional, or global cross-functional teams within the organization. However, the complex structure puts a strain on the organizations capability to align strategies and be truly effective and successful with their launches. While market access input now is already given in the earlier stages of clinical development to support value propositions, the question remains if the current market access organizational structure is fit for the purpose to face the increasing hurdles raised by payers and national health authorities.
Transmineo is a startup that uses modern digital and information technologies to set up a smart organization model to be offered as a service to companies to help commercialize their orphan medicines in Europe in a highly cost-efficient way, while demonstrating value and addressing payer concerns.
We are driven by the urgency to help solve the geographical inequality of access to orphan medicines in Europe by finding smart solutions to offer patients – regardless of their geography – access to orphan drugs, while gaining control over their own disease management.
The Logistics Community Brabant (LCB), the Breda University of Applied Sciences (BUAS) and the Weconomics Foundation are supporting Transmineo with its mission.
All profits made by Keen Access Insights will be invested in building Transmineo’s proof of concept.
If you want to know more about our consulting services or about Transmineo’s mission